Celcuity Inc. Form 8-K Summary
Business Context and Reporting Period
Celcuity Inc. (CELC) filed this Current Report on Form 8-K on July 28, 2025. The filing discloses positive topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 clinical trial. The trial evaluates gedatolisib in combination with fulvestrant, with and without palbociclib, for adults with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer who have progressed on prior CDK4/6 inhibitor and aromatase inhibitor therapy.
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical trial results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
The filing reports statistically significant and clinically meaningful improvements in Progression-Free Survival (PFS) compared to fulvestrant alone:
- Gedatolisib Triplet (gedatolisib + palbociclib + fulvestrant): Reduced risk of disease progression or death by 76% (Hazard Ratio 0.24). Median PFS was 9.3 months versus 2.0 months for fulvestrant, an incremental improvement of 7.3 months.
- Gedatolisib Doublet (gedatolisib + fulvestrant): Reduced risk of disease progression or death by 67% (Hazard Ratio 0.33). Median PFS was 7.4 months versus 2.0 months for fulvestrant, an incremental improvement of 5.4 months.
The company states these hazard ratios and incremental PFS improvements are the most favorable ever reported in Phase 3 trials for this patient population. Additionally, treatment discontinuation rates due to adverse events were lower than observed in prior Phase 1b trials and other approved Phase 3 combinations, with lower rates of hyperglycemia and stomatitis.
Guidance, Outlook, and Risks
Outlook and Milestones:
- Full data from the PIK3CA wild-type cohort will be presented at a medical conference later in 2025.
- The Company expects to submit a New Drug Application (NDA) for gedatolisib to the FDA in the fourth quarter of 2025.
- Topline data for the VIKTORIA-1 PIK3CA mutation cohort is expected by the end of 2025.
Risks and Contingencies:
- Topline results are based on preliminary analysis and may change following comprehensive review.
- There are risks of unforeseen delays in the planned NDA submission.
- Regulatory approval is not guaranteed.
- Forward-looking statements are subject to risks detailed in the Company's 2024 Form 10-K and Q1 2025 Form 10-Q.
Investor Verification Checklist
- Verify the full data presentation at the upcoming medical conference to confirm the preliminary topline results.
- Monitor the timeline for the NDA submission in Q4 2025 and any potential delays.
- Review the safety profile details in the full data release, specifically regarding hyperglycemia and stomatitis rates.
- Track the expected release of topline data for the PIK3CA mutation cohort by the end of 2025.
- Consult the most recent Form 10-K and 10-Q for current cash runway and liquidity status, as this 8-K does not provide financial data.